These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 21247447

  • 1. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.
    Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, Mill JG, Krieger JE, Pereira AC.
    BMC Med Genet; 2011 Jan 19; 12():13. PubMed ID: 21247447
    [Abstract] [Full Text] [Related]

  • 2. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.
    Thromb Res; 2013 Jul 19; 132(1):81-7. PubMed ID: 23726091
    [Abstract] [Full Text] [Related]

  • 3. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS, Jeong YH, Park Y, Yoon SE, Kwon TJ, Park JR, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S.
    Br J Clin Pharmacol; 2012 Apr 19; 73(4):629-40. PubMed ID: 22007612
    [Abstract] [Full Text] [Related]

  • 4. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
    Tang XF, Wang J, Zhang JH, Meng XM, Xu B, Qiao SB, Wu YJ, Chen J, Wu Y, Chen JL, Gao RL, Yuan JQ, Yang YJ.
    Eur J Clin Pharmacol; 2013 May 19; 69(5):1103-12. PubMed ID: 23150151
    [Abstract] [Full Text] [Related]

  • 5. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS.
    Lancet; 2010 Oct 16; 376(9749):1312-9. PubMed ID: 20801494
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.
    Shalia KK, Shah VK, Pawar P, Divekar SS, Payannavar S.
    Indian Heart J; 2013 Oct 16; 65(2):158-67. PubMed ID: 23647895
    [Abstract] [Full Text] [Related]

  • 7. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
    Subraja K, Dkhar SA, Priyadharsini R, Ravindra BK, Shewade DG, Satheesh S, Sridhar MG, Narayan SK, Adithan C.
    Eur J Clin Pharmacol; 2013 Mar 16; 69(3):415-22. PubMed ID: 22955794
    [Abstract] [Full Text] [Related]

  • 8. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML.
    JACC Cardiovasc Interv; 2008 Dec 16; 1(6):620-7. PubMed ID: 19463375
    [Abstract] [Full Text] [Related]

  • 9. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY, Han YL, Zhang XL, Li Y, Yan CH, Kang J.
    EuroIntervention; 2013 Jul 16; 9(3):316-27. PubMed ID: 23872648
    [Abstract] [Full Text] [Related]

  • 10. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH, Kim IS, Park Y, Kang MK, Koh JS, Hwang SJ, Kwak CH, Hwang JY.
    JACC Cardiovasc Interv; 2010 Jul 16; 3(7):731-41. PubMed ID: 20650435
    [Abstract] [Full Text] [Related]

  • 11. Genetic determinants of platelet response to clopidogrel.
    Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A.
    J Thromb Thrombolysis; 2011 Nov 16; 32(4):459-66. PubMed ID: 21706290
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD, Cho HY, Lee YB.
    Br J Clin Pharmacol; 2010 Jan 16; 69(1):27-37. PubMed ID: 20078610
    [Abstract] [Full Text] [Related]

  • 14. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population.
    Rideg O, Háber A, Botz L, Szücs F, Várnai R, Miseta A, Kovács GL.
    Cell Biochem Funct; 2011 Oct 16; 29(7):562-8. PubMed ID: 21826689
    [Abstract] [Full Text] [Related]

  • 15. Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease.
    Ma L, Yuan Y, Li J, Yu C, Zhao J.
    Int J Immunogenet; 2020 Dec 16; 47(6):539-545. PubMed ID: 32862511
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
    Sychev DA, Shprakh VV, Kitaeva EY, Mirzaev KB, Mickhalevich IM.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019 Dec 16; 119(3. Vyp. 2):45-52. PubMed ID: 31184624
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
    Carlquist JF, Knight S, Horne BD, Huntinghouse JA, Rollo JS, Muhlestein JB, May H, Anderson JL.
    Thromb Haemost; 2013 Apr 16; 109(4):744-54. PubMed ID: 23364775
    [Abstract] [Full Text] [Related]

  • 20. [Informativeness of genetic factors for optimization of personalized therapy with clopidogrel].
    Knauér NIu, Lifshits GI, Voronina EN, Koleda NV, Gus'kova EV.
    Kardiologiia; 2013 Apr 16; 53(8):72-5. PubMed ID: 24088005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.